HOME >> BIOLOGY >> NEWS
EMBO honors triple talents of UK scientist, author, broadcaster

UK scientist, author and broadcaster Armand Marie Leroi is the 2006 winner of the EMBO Award for Communication in the Life Sciences. The multi-talented developmental geneticist from Imperial College London receives the award in recognition of his remarkable contributions to science communication. Author of an acclaimed popular science book, Leroi has also written and presented scientific documentaries for TV.

Why are most of us born with one nose, two legs, ten fingers and twenty-four ribs and some of us not? This fundamental question forms the basis for much of Armand Leroi's communication work. It is also the topic of his book Mutants, which tells the fascinating and often misunderstood story of human development and how genetic mutations can provide the key to who we are.

Both book and author have received wide acclaim. UK daily The Independent summed up the comments of many reviewers: "The discovery of a distinguished scientist who can write with such flair and style is cause for rejoicing." In 2004, Mutants won the Guardian First Book Prize and the Aventis Prize for Science Books.

Leroi has also brought this vast, uncharted area of biology to the screen. In 2004 he scripted and presented a powerful TV documentary series called Human Mutants for the UK's Channel 4. The programme was a great success and a similar series, What Makes Us Human, was aired in August 2006. Print journalism has also become familiar territory for the scientist, who is a regular contributor to newspapers like The Times, The Independent and the New York Times.

The EMBO selection panel said of the winner: "Leroi masters the worlds of science writing and broadcasting with the skill and versatility of a seasoned media professional, all the time remaining grounded in the science behind the story. This flair for communication combined with his attention to scientific detail brings a unique voice to the public communication of science."

'"/>

Contact: Lindsay Johnson
lindsay.johnson@embo.org
49-062-218-891-108
European Molecular Biology Laboratory
4-Oct-2006


Page: 1 2

Related biology news :

1. 5 OHSU faculty members singled out for honors
2. Double honors for diabetes researchers
3. Anthropologist given one of nations top scientific honors
4. AIBS honors outstanding contributions to the biological sciences
5. Biotechnology Study Center honors Joan V. Ruderman, Salvador Moncada and Charles N. Serhan
6. AIUM honors ultrasound pioneers at the 2007 AIUM Annual Convention
7. Stevens Center for Science Writings honors Edward O. Wilson with Green Book Award
8. AAAS honors defenders of evolution with Scientific Freedom and Responsibility Award
9. Academy honors 18 for major contributions to science
10. Symposium Changes on Earth honors Yale Geologist Robert Berner
11. SNM honors outstanding contributors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EMBO honors triple talents scientist author broadcaster

(Date:5/20/2013)... Foundation (NSF) planning grant will help establish the Center ... of the University of Illinois at Urbana-Champaign and Worcester ... be devoted to research in drying moist, porous materials ... paper products; chemical products; textiles; and biopharmaceuticals," said Hao ... and human nutrition and the Illinois site director. , ...
(Date:5/20/2013)... at the University of Bristol and published online today ... light on how the brain and inner ear developed ... of Earth Sciences, together with Tom Hbner from the ... 150 million year old dinosaurs. , The two palaeontologists ... lettowvorbecki : a very young (juvenile) individual of ...
(Date:5/19/2013)... reports that white men and women of European descent ... and lesser toe deformities, including hammer or claw toe. ... the heritability of foot disorders in humansappear in ... Wiley on behalf of the American College of Rheumatology ... as 60% of older adults have foot disorders which ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Fossil brain teaser 2Blame your parents for bunion woes 2
(Date:5/21/2013)... ISTANBUL , May 21, 2013 ...  European Dialysis and Transplant Association) is the biggest congress ... renal replacement therapy. Nearly 10,000 participants are in ... discuss the latest research findings. New pioneering studies have ... al. "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ...
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Revolutionary Science, ... automatic colony counter, announced today that they have expanded ... products , the IncuCount, IntelliCount, InCount and ImpressCount. ... sophistication are especially useful in food microbiology and pharmaceutical ... an updated look. A bright white enclosure with ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2
Cached News: